Ana Maria da Cunha Mercante

Ana Maria da Cunha Mercante

Auto-generated profile, based on publicly available information

Ana Maria da Cunha Mercante

Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (ICESP HCFMUSP), São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2024 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
LCLuciana Audi Castroneves
Luciana Audi Castroneves
FMFlavia Mangone
Flavia Mangone
ALAntonio Marcondes Lerario
Antonio Marcondes Lerario
AMAna Maria da Cunha Mercante
Ana Maria da Cunha Mercante
RBRAFAEL LOCH BATISTA
RAFAEL LOCH BATISTA
AHAna Oliveira Hoff
Ana Oliveira Hoff
Context Genetic analysis of sporadic medullary thyroid carcinoma (MTC) has revealed somatic variants in RET, RAS, and occasionally other genes. However, around 20% of patients with sporadic MTC lack a known genetic driver. Objective To uncover potential new somatic or germline drivers, we analyze a distinct cohort of patients with sporadic, very early–onset, and aggressive MTC. Methods Germline and somatic DNA exome sequencing was performed in 19 patients, previously tested negative for germline RET variants. Results Exome sequencing of 19 germline samples confirmed the absence of RET and identified an NF1 pathogenic variant in 1 patient. Somatic sequencing was successful in 15 tumors revealing RET variants in 80%, predominantly p.Met918Thr, which was associated with disease aggressiveness. In RET-negative tumors, pathogenic variants were found in HRAS and NF1. The NF1 germline and somatic variants were observed in a patient without a prior clinical diagnosis of neurofibromatosis type 1, demonstrating that the loss of heterozygosity of NF1 functions as a potential MTC driver. Somatic copy number alterations analysis revealed chromosomal alterations in 53.3% of tumors, predominantly in RET-positive cases, with losses in chromosomes 9 and 22 being the most prevalent. Conclusion This study reveals that within a cohort of early-onset nonhereditary MTC, RET remains the major driver gene. In RET-negative tumors, NF1 and RAS are drivers of sporadic MTC. In addition, in young patients without a RET germline mutation, a careful clinical evaluation with a consideration of germline NF1 gene analysis is ideal to exclude Neurofibromatosis type 1 (NF1).

8 August 2022 in Nutrition and Cancer
Verified
Journal Article
Closed access
Luciane SalaroliLuciane Salaroli
Luciane Salaroli
JFJúlia Rabelo Santos Ferreira
Júlia Rabelo Santos Ferreira
CPCamila Bruneli Do Prado
Camila Bruneli Do Prado
OPOlívia Perim Galvão De Podestá
Olívia Perim Galvão De Podestá
ACAndré Lopes Carvalho
André Lopes Carvalho
TTTatiana Natasha Toporcov
Tatiana Natasha Toporcov
There is still no consensus in the literature regarding the role of coffee in head and neck cancer. Thus, we sought to analyze the cumulative consumption of coffee as a protective factor in the genesis of head and neck cancer in Brazil, one of the main coffee producing countries, from January 2011 to February 2017. We carried out a case-control study in 5 referral centers for head and neck cancer with 839 cases and 842 non-cancer hospital controls matched by sex, data collection center and age group. The results of logistic regression analysis showed that the cumulative consumption of >2 cups of coffee per day is an important protective factor (OR: 0.73, 95% CI: 0.5-0.9) against head and neck cancer. Smoking increased the risk by 22 times (OR: 22.19; 95% CI: 13.7-35.8) in individuals who smoke more than 50 packs per year, and the habit of ingesting more than 155 ml of alcohol per day represented approximately twice as high risk (OR: 2.20; 95% CI: 1.4-3.4). In summary, this study suggests that coffee consumption is associated with a lower chance of head and neck cancer.

11 June 2026 in International Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Open access
LMLeandro Luongo Matos
Leandro Luongo Matos
YGY.L.M. Guimarães
Y.L.M. Guimarães
RNR.F.E. Nunes
R.F.E. Nunes
RZR. Zantieff
R. Zantieff
ÂPÂ.T. Paes
Â.T. Paes
Luiz P. KowalskiLuiz P. Kowalski
Luiz P. Kowalski
The incorporation of depth of invasion (DOI) into the AJCC 8th edition staging system substantially changed risk stratification in oral squamous cell carcinoma (OSCC), with important implications for adjuvant treatment decision-making. This retrospective cohort study was performed to evaluate the impact of adjuvant treatment on the risk of recurrence and mortality in patients with OSCC and DOI >1 cm. Overall, 818 consecutive patients treated surgically for OSCC were included. All possible two-factor interactions (treatment and adverse features) were tested using multivariate models. Patients with OSCC and DOI >1 cm who did not receive postoperative radiotherapy (PORT) had significantly worse disease-specific survival (hazard ratio 4.55, 95% confidence interval 2.89-7.16; P < 0.001). A statistically significant interaction between DOI and PORT was observed across primary outcomes (P-value for interaction ≤0.001), indicating differential treatment effects according to DOI status. Among patients with DOI >1 cm treated with PORT, the excess risk was attenuated (hazard ratio 1.45, 95% confidence interval 1.03-2.05; P = 0.033), with consistent patterns across disease-free survival, loco-regional recurrence-free survival, and overall survival. Significant interaction effects with radiotherapy were also identified for selected high-risk features, including perineural invasion, pT4a/b status, and nodal positivity; no significant interaction was observed for surgical margins or extranodal extension. For concurrent chemotherapy, significant interaction effects were mainly observed for pT4a/b and pN positivity. This study is novel in recognizing the imperative need for PORT in OSCC with DOI >1 cm, independently of other well-established prognostic factors or those deemed high risk for these patients.